禾元生物-U
(688765)
| 流通市值：100.53亿 | | | 总市值：131.42亿 |
| 流通股本：2.73亿 | | | 总股本：3.58亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 27,830,511.39 | 18,274,167.96 | 9,628,104.81 | 47,861,353.23 |
| 营业总成本 | 167,098,214.52 | 110,526,540.09 | 50,498,085.64 | 226,004,752.39 |
| 其他经营收益 | | | | |
| 营业利润 | -107,492,954.71 | -64,301,418.86 | -36,083,196.19 | -157,607,699.54 |
| 利润总额 | -105,892,887.64 | -62,756,540.53 | -36,045,931.95 | -157,037,347.83 |
| 净利润 | -105,892,887.64 | -62,756,540.53 | -36,045,931.95 | -157,037,347.83 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | -105,892,887.64 | -62,756,540.53 | -36,045,931.95 | -157,037,347.83 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 1,767,945,698.29 | 1,880,943,890.05 | 1,877,813,174.44 | 2,162,102,820.08 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,135,923,119.83 | 1,969,642,589.49 | 1,763,419,308.43 | 1,540,785,483.85 |
| 资产总计 | 3,903,868,818.12 | 3,850,586,479.54 | 3,641,232,482.87 | 3,702,888,303.93 |
| 流动负债: | | | | |
| 流动负债合计 | 692,892,820.46 | 627,258,046.99 | 566,414,471.62 | 453,597,268.05 |
| 非流动负债: | | | | |
| 非流动负债合计 | 408,554,039.18 | 379,612,708.89 | 206,214,232.88 | 351,400,011.36 |
| 负债合计 | 1,101,446,859.64 | 1,006,870,755.88 | 772,628,704.5 | 804,997,279.41 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,802,421,958.48 | 2,843,715,723.66 | 2,868,603,778.37 | 2,897,891,024.52 |
| 股东权益合计 | 2,802,421,958.48 | 2,843,715,723.66 | 2,868,603,778.37 | 2,897,891,024.52 |
| 负债和股东权益合计 | 3,903,868,818.12 | 3,850,586,479.54 | 3,641,232,482.87 | 3,702,888,303.93 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 130,805,148.02 | 64,395,819.18 | 19,294,559.97 | 154,152,435.22 |
| 经营活动现金流出小计 | 236,813,730.22 | 159,654,036.52 | 68,817,772.56 | 282,471,400.6 |
| 经营活动产生的现金流量净额 | -106,008,582.2 | -95,258,217.34 | -49,523,212.59 | -128,318,965.38 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 484,689,864.5 | 800,830,000 | 75,000,000 | - |
| 投资活动现金流出小计 | 765,427,274.52 | 333,715,157.95 | 233,847,042.4 | 1,848,888,635.46 |
| 投资活动产生的现金流量净额 | -280,737,410.02 | 467,114,842.05 | -158,847,042.4 | -1,848,888,635.46 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 322,299,205 | 322,299,205 | 24,900,000 | 2,868,495,138.33 |
| 筹资活动现金流出小计 | 343,611,717.47 | 340,670,466.78 | 87,246,814.67 | 382,220,746.24 |
| 筹资活动产生的现金流量净额 | -21,312,512.47 | -18,371,261.78 | -62,346,814.67 | 2,486,274,392.09 |
| 汇率变动对现金及现金等价物的影响 | -42,908.96 | -26,615.02 | 239.62 | -27,873.47 |
| 现金及现金等价物净增加额 | -408,101,413.65 | 353,458,747.91 | -270,716,830.04 | 509,038,917.78 |
| 期末现金及现金等价物余额 | 261,339,838.79 | 1,022,900,000.35 | 398,724,422.4 | 669,441,252.44 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 353,458,747.91 | - | 509,038,917.78 |